1061682-96-9 Usage
Molecular weight
414.4 g/mol This is the mass of one mole of ipratropium bromide, which is calculated by adding the atomic weights of all the atoms in the molecular formula.
Appearance
White to pale brown powder This describes the physical appearance of ipratropium bromide in its solid form.
Solubility
Slightly soluble in water, soluble in chloroform and ethanol This indicates the solubility of ipratropium bromide in different solvents.
Mechanism of action
Anticholinergic Ipratropium bromide works by blocking the action of acetylcholine, a neurotransmitter that causes the muscles in the airways to constrict.
Indications
Chronic obstructive pulmonary disease (COPD), asthma Ipratropium bromide is used to treat respiratory conditions such as COPD and asthma.
Administration
Inhalation Ipratropium bromide is commonly administered through inhalation using devices such as metered dose inhalers or nebulizers.
Combination with other medications
Albuterol Ipratropium bromide is often combined with other medications, such as albuterol, to enhance its effectiveness.
Safety and efficacy
Considered safe and effective Ipratropium bromide is considered a safe and effective treatment for managing respiratory symptoms and improving lung function in patients with obstructive airway diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 1061682-96-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,1,6,8 and 2 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1061682-96:
(9*1)+(8*0)+(7*6)+(6*1)+(5*6)+(4*8)+(3*2)+(2*9)+(1*6)=149
149 % 10 = 9
So 1061682-96-9 is a valid CAS Registry Number.
1061682-96-9Relevant academic research and scientific papers
AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS
-
Page/Page column 35, (2010/06/16)
The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment
